Novocure Announces 35 Presentations on Tumor Treating Fields at the American Association for Cancer Research Annual Meeting 2018
The clinical and preclinical research to be presented includes the application of Tumor Treating Fields in seven cancer types
ST. HELIER, Jersey–(BUSINESS WIRE)–
The volume of Tumor Treating Fields presentations marks a record number of abstracts for
“Over the past several years, the volume of presentations on Tumor Treating Fields at the AACR Annual Meeting has increased substantially, demonstrating what we believe to be an increased interest in Tumor Treating Fields from the scientific community,” said Dr.
(Abstract CT086) Safety of TTFields and radiotherapy (RT) for newly diagnosed glioblastoma: Interim safety results from a pilot study. R. Grossman.
(Abstract #CT081) Tumor treating fields in combination with Bevacizumab in recurrent or progressive meningioma in a phase 2 study. P. Kumthekar.
(Abstract #CT082) TTFields concurrent with standard of care for the treatment of stage 4 non-small cell lung cancer (NSCLC) following platinum failure: Phase 3 LUNAR study. U. Weinberg.
(Abstract #CT084) HEPANOVA: A phase 2 trial of tumor treating fields concomitant with sorafenib for advanced hepatocellular carcinoma. A. Grosu.
(Abstract #CT105) Safety of TTFields applied to the torso: A meta-analysis of 176 patients from four phase I-II trials. I. Vergote.
(Abstract #CT108) Tumor Treating Fields (TTFields) in combination with Lomustine (CCNU) in the EF-14 phase 3 clinical study – A safety analysis. A. Kinzel.
(Abstract #CT092) Effect of Tumor treating fields in children with recurrent or progressive high-grade glioma and ependymoma;
(Abstract #CT100) Effects of Tumor Treating Fields (TTFields) on health-related quality of life (HRQoL) in newly diagnosed glioblastoma: An exploratory analysis of the EF-14 randomized phase III trial. T. Walbert.
(Abstract #CT157) PANOVA-3: A phase 3 study of TTFields with nab-paclitaxel and gemcitabine for front-line treatment of locally-advanced pancreatic adenocarcinoma (LAPC). U. Weinberg.
(Abstract #CT138) Open-label personalized targeted intervention to maximize TTFields intensity in recurrent GBM (OptimalTTF Trial). N. Mikic.
(Abstract #LB-257) Incremental cost-effectiveness ratio of tumor treating fields for newly diagnosed glioblastoma. G. Guzauskas.
(Abstract #CT151) TTFields and radiosurgery for 1 to 10 brain metastases from NSCLC in the phase III METIS study. M. Mehta.
(Abstract # CT097) Quantitative MR measurements in glioblastoma patients: mean diffusivity with Tumor Treating Fields plus standard therapy versus standard treatment alone. J. Vymazal.
(Abstract #676) Preliminary investigation into the dosimetric impact of tumor treating field arrays on concurrent radiotherapy for newly-diagnosed glioblastoma. G. Stachelek.
(Abstract #621) Evaluating the compatibility of Tumor Treating electric Fields with key anti-tumoral T cell functions. G. Diamant.
(Abstract #1343) Induction of autophagy following TTFields application serves as a survival mechanism mediated by AMPK activation. A. Shteingauz.
(Abstract #1860) Tumor-Treating-Fields (TTFields) effects on glioblastoma cells are augmented by mitotic checkpoint inhibition. A. Kessler.
(Abstract #1865) The combined treatment of 150 kHz Tumor Treating Fields (TTFields) and Sorafenib inhibit hepatocellular carcinoma in vitro. K. Gotlib.
(Abstract #1463) Efficacy of Tumor Treating Fields (TTFields) and aurora B kinase inhibitor. D. Krex.
(Abstract #1707) Tumor Treating Fields Exert Cellular and Immunologic Effects. E. Wong.
(Abstract #2273) Meta-analysis of cancer cell lines based on their response to Tumor Treating Fields (TTFields).
(Abstract #2284) Semi-automated MRI segmentation workflow for glioblastoma treated by Tumor Treating Fields.
(Abstract #3199) Computational studies show that Tumor Treating Fields can be delivered to the infratentorial brain at therapeutic levels. S. Levy.
(Abstract #3195) The molecular mechanism of action and the cellular targets of TTFields. A. Kalra.
(Abstract #3204) Transducer array configuration optimization for treatment of pancreatic cancer using Tumor Treating Fields (TTFields) A. Naveh.
(Abstract #3209) Numerical modeling of intracellular mechanisms in tumor-treating fields. K.
(Abstract #3217) Newly identified role of tumor treating fields in DNA damage repair and replication stress pathways.
(Abstract #3208) Optimal array layouts for tumor treating fields therapy in glioblastoma – oblique array layouts are superior to standard LR and AP positions. N. Mikic.
(Abstract #4194) Tumor Treating Fields (TTFields) affect invasion properties and cell morphology of various cancer cells in vitro. R. S. Schneiderman.
(Abstract #4398) In vitro Tumor Treating Fields (TTFields) alter proliferation and morphology of patient-derived high-grade meningioma cell lines.
(Abstract #4376) Tumor Treating Fields (TTFields) decrease proliferation of patient-derived lung cancer brain metastasis cells in vitro. S. K. Michelhaugh.
(Abstract #4111) Water content based Electrical Properties Tomography (wEPT) for modelling delivery of Tumor Treating Fields to the brain.
(Abstract #4637) Tumor Treating Fields (TTFields) have anti-proliferative effects on high-grade paediatric brain tumor cell lines. J. Branter.
(Abstract #5828) Withaferin A and Tumor Treating Fields synergistically inhibit glioma proliferation. E. Chang.
(Abstract #5898) A Systems Approach for Determining the Mechanism of Resistance to Tumor Treating Fields in Glioblastoma. C. Dongjiang.
Headquartered in Jersey,
In addition to historical facts or statements of current condition, this press release may contain forward-looking statements. Forward-looking statements provide Novocure’s current expectations or forecasts of future events. These may include statements regarding anticipated scientific progress on its research programs, development of potential products, interpretation of clinical results, prospects for regulatory approval, manufacturing development and capabilities, market prospects for its products, and other statements regarding matters that are not historical facts. You may identify some of these forward-looking statements by the use of words in the statements such as “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe” or other words and terms of similar meaning. Novocure’s performance and financial results could differ materially from those reflected in these forward-looking statements due to general financial, economic, regulatory and political conditions as well as more specific risks and uncertainties facing
Media and Investor Contact:
Ashley Cordova, 212-767-7558